Galectin Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
Galectin Therapeutics(GALT.US) Director Buys US$5,949.75 in Common Stock
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
Express News | Galectin Therapeutics Inc: Navigate Trial Remains on Track for Interim Top-Line Readout Late in Q4 of 2024
Express News | As Of March 31, 2024, Galectin Therapeutics Had $23.6M Of Cash And Cash Equivalents. Additionally, The Company Has $10M Remaining Available Under A $60M Line Of Credit Expected To Provide Cash Runway Into May 2025
Express News | Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
Express News | Galectin Therapeutics Q1 Operating Income USD -9.648 Million
Express News | Galectin Therapeutics Q1 EPS USD -0.19
Express News | Galectin Therapeutics Q1 Net Income USD -11.489 Million
Galectin Therapeutics Had $23.6M of Cash and Cash Equivalents at March 31 >GALT
Press Release: Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
Express News | Galectin Therapeutics Q1 2024 GAAP EPS $(0.19) Misses $(0.16) Estimate
Express News | Galectin Therapeutics Inc- Qtrly Shr Loss $0.19
Express News | Galectin Therapeutics - Believes It Has Sufficient Cash to Fund Currently Planned Operations, Research and Development Activities Through May 15, 2025
Galectin Therapeutics | 10-Q: Quarterly report
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
Galectin Therapeutics(GALT.US) Director Buys US$3,520 in Common Stock
Galectin Therapeutics(GALT.US) Officer Buys US$3,390 in Common Stock
Galectin Therapeutics(GALT.US) 10% Shareholder Sells US$76,500 in Common Stock
Galectin Therapeutics And 2 Other Penny Stocks Insiders Are Buying
No Data